We study the pathophysiology of benign and malignant hematologic disorders using biochemical and biophysical methods. Recently, we uncovered two endothelial bound enzymes on the cerebral vasculature that induce platelet aggregation via the hydrolysis of a small molecule released by platelets upon degranulation. We have proposed that these enzymes are unrecognized factors capable of inducing central hemostasis/stroke, a hypothesis supported by recent genomic studies revealing genes conferring stroke protection to patients at risk for thrombotic stroke (see press release).
Associate Professor of Pathology
Inozyme Pharmaceuticals aims to develop a therapy for an ultra-rare infant disorder—this is based on the work of Yale University pathologist Demetrios Braddock.